| Name | Title | Contact Details |
|---|
Ready Medical Inc is a Paramount, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Robert Bosch Healthcare is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
San Antonio AIDS Foundation is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians and scientists in New York City and around the world. The doctors and scientists of Weill Cornell Medicine — faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side`s scientific corridor, Weill Cornell Medicine`s powerful network of collaborators extends to its parent university Cornell University; to Qatar, where Weill Cornell Medicine-Qatar offers a Cornell University medical degree; and to programs in Tanzania, Haiti, Brazil, Austria, and Turkey. Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Lower Manhattan Hospital, and NewYork-Presbyterian Queens. Weill Cornell Medicine is also affiliated with Houston Methodist. At Weill Cornell Medicine, we connect the collective power of our integrated partners in education and research to provide world-class care for our individual patients—#CareDiscoverTeach.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.